CEBPZ and Parkinson disease: Ongoing work is already validating this approach in pharmacological MRI, assessing the drug-target mechanisms behind CBF-based functional changes induced by selective serotonin reuptake inhibitors (SSRIs), and in clinical cohorts where a known deficit such as dopamine loss in Parkinson’s Disease likely affects the normal functioning of networks related to specific molecular pathways.